Skip to main content

Multiple Myeloma Learning Library

New & Trending

Beth Faiman, CNP, PhD, Cleveland Clinic
Videos
07/21/2025
Beth Faiman, CNP, PhD
Beth Faiman, CNP, PhD, discusses treatment decision-making for a patient with multiple myeloma whose disease relapsed through several lines of therapy.
Beth Faiman, CNP, PhD, discusses treatment decision-making for a patient with multiple myeloma whose disease relapsed through several lines of therapy.
Beth Faiman, CNP, PhD, discusses...
07/21/2025
Oncology Learning Network APP Institute
Beth Faiman, CNP, PhD, Cleveland Clinic
Videos
07/21/2025
Beth Faiman, CNP, PhD
Beth Faiman, CNP, PhD, discusses treatment decision-making for a patient with symptomatic relapsed multiple myeloma.
Beth Faiman, CNP, PhD, discusses treatment decision-making for a patient with symptomatic relapsed multiple myeloma.
Beth Faiman, CNP, PhD, discusses...
07/21/2025
Oncology Learning Network APP Institute
Beth Faiman & Donna Catamero
Clinical Pearls
07/11/2025
Beth Faiman, CNP, PhD; Donna Catamero, NP
Beth Faiman, CNP, PhD, and Donna Catamero, NP, discuss updates in multiple myeloma from the 2025 ASCO Annual Meeting and EHA Congress, highlighting pivotal studies exploring the use of bispecifics in earlier lines of treatment and emerging...
Beth Faiman, CNP, PhD, and Donna Catamero, NP, discuss updates in multiple myeloma from the 2025 ASCO Annual Meeting and EHA Congress, highlighting pivotal studies exploring the use of bispecifics in earlier lines of treatment and emerging...
Beth Faiman, CNP, PhD, and Donna...
07/11/2025
Oncology Learning Network APP Institute
Beth Faiman & Donna Catamero
Clinical Pearls
07/11/2025
Beth Faiman, CNP, PhD; Donna Catamero, NP
Beth Faiman, CNP, PhD, and Donna Catamero, NP, discuss bispecific antibody therapy for multiple myeloma and important considerations for patient selection and side effect management, highlighting recent data and real-world applications.
Beth Faiman, CNP, PhD, and Donna Catamero, NP, discuss bispecific antibody therapy for multiple myeloma and important considerations for patient selection and side effect management, highlighting recent data and real-world applications.
Beth Faiman, CNP, PhD, and Donna...
07/11/2025
Oncology Learning Network APP Institute
Caroline Schinke, MD
Oncology Advances
08/09/2024
Caroline Schinke, MD, Myeloma Center at the University of Arkansas, speaks about the long-term efficacy and safety results from the MonumenTAL-1 trials on talquetamab treatment among patients with MM.
Caroline Schinke, MD, Myeloma Center at the University of Arkansas, speaks about the long-term efficacy and safety results from the MonumenTAL-1 trials on talquetamab treatment among patients with MM.
Caroline Schinke, MD, Myeloma...
08/09/2024
Oncology Learning Network APP Institute
Samantha Shenoy
Videos
05/09/2024
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses...
05/09/2024
Oncology Learning Network APP Institute
Beth Finley-Oliver and Rachid Baz, Moffitt Cancer Center
Clinical Pearls
11/27/2023
Elizabeth Finley-Oliver, ARNP, MSN; Rachid Baz, MD
Elizabeth Finley-Oliver, MSN, ARNP, AGNP-BC, and Rachid Baz, MD, discuss the treatment landscape for patients with multiple myeloma and how clinicians can individualize care while addressing patient needs.
Elizabeth Finley-Oliver, MSN, ARNP, AGNP-BC, and Rachid Baz, MD, discuss the treatment landscape for patients with multiple myeloma and how clinicians can individualize care while addressing patient needs.
Elizabeth Finley-Oliver, MSN,...
11/27/2023
Oncology Learning Network APP Institute
Lorinda Coombs
APP Perspectives
11/17/2023
Lorinda Coombs, PhD, CNS, FNP-BC
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS,...
11/17/2023
Oncology Learning Network APP Institute

Clinical Pearls

APP Perspectives

Lorinda Coombs
APP Perspectives
11/17/2023
Lorinda Coombs, PhD, CNS, FNP-BC
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS,...
11/17/2023
Oncology Learning Network APP Institute
Lorinda Coombs
APP Perspectives
11/17/2023
Lorinda Coombs, PhD, CNS, FNP-BC
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS,...
11/17/2023
Oncology Learning Network APP Institute

Conference Coverage

Lorinda Coombs
APP Perspectives
11/17/2023
Lorinda Coombs, PhD, CNS, FNP-BC
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS,...
11/17/2023
Oncology Learning Network APP Institute
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP
Conference Coverage
01/30/2026
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP, reviewed the mechanisms, expanding clinical use, and payload-driven toxicities of antibody-drug conjugates, emphasizing practical strategies for toxicity recognition, management, and optimizing patient...
Sri Kota, MSN, BA, APN, AGNP-C, AOCNP, reviewed the mechanisms, expanding clinical use, and payload-driven toxicities of antibody-drug conjugates, emphasizing practical strategies for toxicity recognition, management, and optimizing patient...
Sri Kota, MSN, BA, APN, AGNP-C,...
01/30/2026
Oncology Learning Network APP Institute
Jessica Walchonski, PA-C, MMS
Conference Coverage
01/23/2026
Jessica Walchonski, PA-C, MMS
Jessica Walchonski, PA-C, MMS, reviewed recent advances in gynecologic oncology, highlighting new targeted and immunotherapy options for ovarian cancer and evolving strategies for endometrial cancer at the 2025 Oncology Learning Network APP...
Jessica Walchonski, PA-C, MMS, reviewed recent advances in gynecologic oncology, highlighting new targeted and immunotherapy options for ovarian cancer and evolving strategies for endometrial cancer at the 2025 Oncology Learning Network APP...
Jessica Walchonski, PA-C, MMS,...
01/23/2026
Oncology Learning Network APP Institute
Allison Tanner, PA-C
Conference Coverage
01/16/2026
Allison Tanner, PA-C
Allison Tanner, PA-C, reviewed the recognition and management of CRS, ICANS, and other evolving toxicities associated with CAR T-cell therapy and bispecific antibodies, emphasizing the need for clinician readiness as cellular therapies...
Allison Tanner, PA-C, reviewed the recognition and management of CRS, ICANS, and other evolving toxicities associated with CAR T-cell therapy and bispecific antibodies, emphasizing the need for clinician readiness as cellular therapies...
Allison Tanner, PA-C, reviewed...
01/16/2026
Oncology Learning Network APP Institute
Amy Goodrich, RN, BSN, MSN, CRNP-AC
Conference Coverage
01/08/2026
Amy Goodrich, RN, BSN, MSN, CPNP-AC
Amy Goodrich, RN, BSN, MSN, CRNP-AC, reviewed emerging treatments and the growing challenges of therapy sequencing in DLBCL, FL, and CLL, emphasizing individualized approaches guided by patient characteristics and evolving data.
Amy Goodrich, RN, BSN, MSN, CRNP-AC, reviewed emerging treatments and the growing challenges of therapy sequencing in DLBCL, FL, and CLL, emphasizing individualized approaches guided by patient characteristics and evolving data.
Amy Goodrich, RN, BSN, MSN,...
01/08/2026
Oncology Learning Network APP Institute
Beth Sandy, MSN, CRNP, FAPO
Conference Coverage
01/05/2026
Beth Sandy, MSN, CRNP, FAPO
Beth Sandy, MSN, CRNP, FAPO, reviewed the clinical use and toxicity management of tyrosine kinase inhibitors across solid tumors at the 2025 Oncology Learning Network APP Institute.
Beth Sandy, MSN, CRNP, FAPO, reviewed the clinical use and toxicity management of tyrosine kinase inhibitors across solid tumors at the 2025 Oncology Learning Network APP Institute.
Beth Sandy, MSN, CRNP, FAPO,...
01/05/2026
Oncology Learning Network APP Institute
Kevin Chen, PharmD, MS, BCOP, CPP
Conference Coverage
12/17/2025
Kevin Chen, PharmD, MS, BCOP
Kevin Chen, PharmD, discussed the increase in recent biomarker-driven drug approvals for solid tumors at the 2025 JADPRO Annual Conference, highlighting their targeted efficacy, unique toxicity profiles, and the need for clinicians to stay up...
Kevin Chen, PharmD, discussed the increase in recent biomarker-driven drug approvals for solid tumors at the 2025 JADPRO Annual Conference, highlighting their targeted efficacy, unique toxicity profiles, and the need for clinicians to stay up...
Kevin Chen, PharmD, discussed...
12/17/2025
Oncology Learning Network APP Institute
Shila Pandey, DNP, AGPCNP-BC, ACHPN, FPCN
Conference Coverage
12/11/2025
Shila Pandey, DNP, AGPCNP-BC, ACHPN
At the 2025 JADPRO meeting, Shila Pandey, DNP, shared insights into the development of an advanced-practice-provider-led quality assurance committee designed to improve patient safety and care quality.
At the 2025 JADPRO meeting, Shila Pandey, DNP, shared insights into the development of an advanced-practice-provider-led quality assurance committee designed to improve patient safety and care quality.
At the 2025 JADPRO meeting,...
12/11/2025
Oncology Learning Network APP Institute
Danielle Roman, PharmD, BCOP
Conference Coverage
12/11/2025
Danielle Roman, PharmD
Danielle Roman, PharmD, highlighted evolving treatment strategies for hormone receptor–positive, HER2-positive metastatic breast cancer, emphasizing the integration of HER2-targeted therapies, endocrine therapy, and emerging CDK4/6 inhibitors...
Danielle Roman, PharmD, highlighted evolving treatment strategies for hormone receptor–positive, HER2-positive metastatic breast cancer, emphasizing the integration of HER2-targeted therapies, endocrine therapy, and emerging CDK4/6 inhibitors...
Danielle Roman, PharmD,...
12/11/2025
Oncology Learning Network APP Institute
Ashley Ochoa, MBA, CFHP, CRCR, CPC, COC, CMOM-HEMONC
Videos
11/07/2025
Ashley Ochoa, MBA, CFHP, CRCR, CPC, COC, CMOM-HEMONC
Ashley Ochoa, MBA, CFHP, CRCR, discusses how implementing a strong financial navigation program optimizes oncology patient outcomes and improves the revenue cycle at the 2025 AONN+ Annual Conference.
Ashley Ochoa, MBA, CFHP, CRCR, discusses how implementing a strong financial navigation program optimizes oncology patient outcomes and improves the revenue cycle at the 2025 AONN+ Annual Conference.
Ashley Ochoa, MBA, CFHP, CRCR,...
11/07/2025
Oncology Learning Network APP Institute
Matthew Zachary
Videos
11/06/2025
Matthew Zachary
Matthew Zachary discusses the evolving landscape of culture, policy, and patient empowerment in his keynote address at the 2025 Academy of Oncology Nurse & Patient Navigators Annual Conference.
Matthew Zachary discusses the evolving landscape of culture, policy, and patient empowerment in his keynote address at the 2025 Academy of Oncology Nurse & Patient Navigators Annual Conference.
Matthew Zachary discusses the...
11/06/2025
Oncology Learning Network APP Institute